Zoetis (ZTS)
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
$89.20+7.48%
Close 2026-11-04 · 1-day change
NYSEHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-11-04
Research Workspace
Put ZTS beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Pharmaceuticals is in expansion. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Primary pillar under pressure — Achieve EPS near guidance: Diluted EPS: $1.65 per share.
View ThesisRevenue growth is slowing — up about 1% over the past year and decelerating.
View GrowthRanks among the strongest in its industry on quality — around the top 8%.
View QualityManagement screens strong on capital allocation, earnings delivery.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationModerate volatility — typically moves about 1% a day.
View RiskZoetis needs new product approvals to drive revenue growth. This growth engine must keep compounding to justify the price. Revenue grew 3% year over year in the latest quarter. The company beat its earnings estimate by 1.6%. It trades at 12 times earnings versus a 16 times peer median. The market is pricing in more growth than we forecast. Companion animal weakness threatens the revenue growth objective. Our model puts the next-quarter miss probability near 26%. Peer multiples imply a price about 17% below where it trades. The thesis is on watch. This read is provisional.
Trailing returns as of 2026-11-04. ZTS is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 16 analysts currently covering ZTS (as of Nov 2026).
Based on 6 Wall Street analysts offering 12-month price targets for ZTS in the last 4 months.
Continue this research
Compare ZTS with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| ZTS Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 12 valuation methods, at three horizons. As of 2026-11-05. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Pharmaceuticals — fair value, gap to price, and forward P/E.
Our valuation methods disagree too much on this name right now. Rather than print a number we don't believe, we're holding it back until they converge.
Compare the value case
Put ZTS next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Threatens: Drive revenue growth with new product approvals
Companion animal weakness may hinder revenue growth.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-11-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $89.20
The last 12 months of price, then the range of analyst 12-month targets from today’s $89.20.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 10% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.
New competition could hinder revenue growth objectives.
Advances: Drive revenue growth with new product approvals
Pipeline developments support revenue growth strategy.
Threatens: Revenue growth guidance for 2026
Earnings revision may impact revenue growth guidance.
Advances: Drive revenue growth with new product approvals
New product approval supports revenue growth objective.
Threatens: Revenue growth guidance for 2026
Stock price target cut indicates revenue growth concerns.
Threatens: Revenue growth guidance for 2026
Concerns about growth story impact future guidance.
Leadership changes may impact strategic execution and guidance.